TPO is a lineage-specific growth factor, which is produced primarily by the liver, kidneys, and skeletal muscle. Platelets can circulate freely in the body, and megakaryocytes can proliferate and mature more quickly because it stimulates their activity. To regulate platelets, TPO interacts with them through the receptor c-mp, found on their surface. TPO has shown cross-species responsiveness between humans and mice.
TPO is fully functional in the human body. There are 353 amino acids in the human TPO gene, composed of a signal sequence of 21 amino acids, an erythropoietin-like domain of 15 amino acids, and a heavily glycosylated C-terminal portion of 179 amino acids. Recombinant There is an erythropoietin-like domain inside the human TPO polypeptide, which includes 174 amino acids and weighs 18.6 kilodaltons.
Thrombopoietin is a glycoprotein hormone that regulates the production of platelets in the bone marrow. The liver and kidneys produce the bulk of this hormone. Megakaryocytes, which are cells in the bone marrow that may become platelets, and their differentiation, are encouraged by this treatment.
Since this is the preferred approach, lyophilized thrombopoietin should be reconstituted in sterile PBS with 0.1 percent endotoxin-free recombinant HSA before use.
Lyophilized thrombopoietin is stable at room temperature for three weeks but must be maintained below -18 degrees Celsius to preserve its potency and shelf life. TPO should be stored at 4 degrees Celsius between 2 and 7 days after reconstitution and at -18 degrees Celsius for long-term storage. Here the tpo human recombinant by Shenandoah Biotech is essential.
- The Use Of A Carrier Protein Is Recommended When Keeping For A Long Length Of Time (0.1 Percent HSA Or BSA)
The transcription factor TPO has a considerable impact on both megakaryocytopoiesis and thrombopoiesis. TPO binds to its receptor, a cellular homolog of the myeloproliferative leukemia virus oncogene (c-Mpl), and activates this receptor to promote megakaryocyte proliferation and maturation. To complete the signal transduction process, MPL must establish connections with intracytoplasmic tyrosine kinases, such as JAK2, found in cells.
JAK2 regulates both the stability of MPL and its expression on the cell surface. These stem cells and progenitor cells have the potential to regenerate and multiply in number because of TPO’s ability to stimulate their maintenance and proliferation. Blood and bone marrow TPO levels and platelet count are inversely related.
TPO has up-regulated in bone marrow stromal cells by PDGF and FGF-2, whereas it is down-regulated by thrombospondin, PF4, and TGF- in these cells. The c-Mpl receptor regulates the body’s TPO levels. HGF increases the mRNA expression of TPO in hepatocytes. To activate TPO transcription in the liver during the acute phase of the immune response, an enzyme called IL-6 is required. Coronary syndromes, Thrombocytopenia, and sepsis are a few of the hematological disorders associated with high plasma TPO levels.
TPO is also generated in the brain, which promotes the death of hypoxia-sensitive neurons and delays neuronal growth by blocking NGF-induced signaling. NGF is required for both of these procedures to take place. TPO levels are elevated in the cerebral fluid of some persons with bacterial or viral meningitis, although this is not always the case. Bacteria and viruses may both cause meningitis.